Exabis Library
Welcome to the e-CCO Library!
P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P333: The baseline features of patients with newly diagnosed moderate-to-severe ulcerative colitis in Korea: A population-based cohort study (the MOSAIK cohort)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P334: Chromoendoscopy is superior to white light endoscopy for the detection of advanced colonic neoplasia in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P334: Does the circadian clock have a role in the pathogenesis of inflammatory bowel disease (IBD)?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P334: Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P334: Evolution of a long-term follow-up cohort of Crohn’s disease with complex perianal fistula: from antibiotic to combined AZA and anti-TNF based treatment ending up clinical and radiological healing with or without stoma
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P334: Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P334: Respiratory Manifestations and Association Between Disease Activity in Patients with Inflammatory Bowel Disease in a Reference Center in Salvador, Bahia, Brazil.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P334: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P335 Treatment strategies after mucosal healing (MH) in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P335: A prospective multicentre “real-life” international validation study of the PICaSSO endoscopic scoring system against histologic scoring system to define mucosal healing in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P335: Cancer recurrence with immunosuppressive therapy in immune-mediated diseases: a systematic review and meta-analysis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P335: Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P335: Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P335: Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P335: Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P335: Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with Biologics
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P336 Minimally invasive surgery is safe and feasible for luminal Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P336: Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM